Opus Capital Group’s AbbVie ABBV Stock Holding History

Opus Capital Group’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$442K	Sell	2,030 -629	-24%	-$140K	0.05%	85
2025 Q4	$608K	Sell	2,659 -451	-15%	-$103K	0.07%	68
2025 Q3	$720K	Sell	3,110 -177	-5%	-$36K	0.08%	62
2025 Q2	$610K	Hold	3,287	–	–	0.07%	65
2025 Q1	$689K	Sell	3,287 -192	-6%	-$37.3K	0.09%	60
2024 Q4	$618K	Sell	3,479 -769	-18%	-$141K	0.08%	60
2024 Q3	$839K	Sell	4,248 -17	-0.4%	-$3.17K	0.1%	55
2024 Q2	$732K	Buy	4,265 +157	+4%	+$26K	0.1%	61
2024 Q1	$748K	Sell	4,108 -537	-12%	-$92.5K	0.11%	63
2023 Q4	$720K	Sell	4,645 -26	-0.6%	-$3.79K	0.12%	61
2023 Q3	$696K	Sell	4,671 -436	-9%	-$64K	0.12%	55
2023 Q2	$688K	Buy	5,107 +249	+5%	+$36.5K	0.12%	59
2023 Q1	$774K	Sell	4,858 -55	-1%	-$8.41K	0.14%	55
2022 Q4	$794K	Buy	4,913 +36	+0.7%	+$5.52K	0.15%	50
2022 Q3	$655K	Sell	4,877 -30	-0.6%	-$4.3K	0.14%	50
2022 Q2	$752K	Buy	4,907 +80	+2%	+$12.2K	0.15%	49
2022 Q1	$783K	Buy	4,827 +283	+6%	+$41.1K	0.15%	51
2021 Q4	$615K	Buy	4,544 +8	+0.2%	+$945	0.13%	55
2021 Q3	$489K	Sell	4,536 -1,500	-25%	-$171K	0.11%	62
2021 Q2	$680K	Sell	6,036 -523	-8%	-$58.9K	0.15%	56
2021 Q1	$710K	Sell	6,559 -1,220	-16%	-$130K	0.17%	54
2020 Q4	$834K	Buy	7,779 +739	+10%	+$71K	0.21%	52
2020 Q3	$617K	Buy	7,040 +174	+3%	+$16.4K	0.18%	61
2020 Q2	$674K	Buy	6,866 +1,876	+38%	+$165K	0.21%	58
2020 Q1	$380K	Buy	+4,990	New	+$425K	0.13%	70
2019 Q1	–	Sell	-7,404	Closed	-$683K	–	216
2018 Q4	$683K	Sell	7,404 -1,865	-20%	-$164K	0.14%	121
2018 Q3	$877K	Sell	9,269 -935	-9%	-$88.7K	0.2%	116
2018 Q2	$945K	Hold	10,204	–	–	0.23%	106
2018 Q1	$966K	Sell	10,204 -200	-2%	-$22K	0.24%	108
2017 Q4	$1.01M	Buy	10,404 +1,377	+15%	+$130K	0.22%	108
2017 Q3	$802K	Buy	9,027 +689	+8%	+$52.4K	0.18%	109
2017 Q2	$604K	Sell	8,338 -1,364	-14%	-$91.7K	0.12%	114
2017 Q1	$632K	Hold	9,702	–	–	0.08%	120
2016 Q4	$607K	Sell	9,702 -1,898	-16%	-$116K	0.09%	112
2016 Q3	$732K	Sell	11,600 -4,290	-27%	-$278K	0.15%	106
2016 Q2	$983K	Sell	15,890 -824	-5%	-$50.2K	0.22%	99
2016 Q1	$955K	Buy	16,714 +925	+6%	+$51.6K	0.21%	107
2015 Q4	$935K	Sell	15,789 -465	-3%	-$26.8K	0.16%	121
2015 Q3	$884K	Hold	16,254	–	–	0.15%	124
2015 Q2	$1.09M	Sell	16,254 -1,040	-6%	-$67.9K	0.17%	116
2015 Q1	$1.01M	Buy	17,294 +1,690	+11%	+$102K	0.16%	123
2014 Q4	$1.02M	Sell	15,604 -2,305	-13%	-$145K	0.15%	118
2014 Q3	$1.03M	Buy	17,909 +500	+3%	+$27.8K	0.14%	130
2014 Q2	$983K	Hold	17,409	–	–	0.07%	120
2014 Q1	$895K	Buy	+17,409	New	+$880K	0.06%	114

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Opus Capital Group's ABBV Position: Q1 2026 in Review

Opus Capital Group reduced its AbbVie (ABBV) stake by 24% in Q1 2026, selling an estimated $140K and leaving 2,030 shares worth $442K. The position accounts for 0.05% of the portfolio, ranked #85.

Opus Capital Group first reported a position in ABBV in Q1 2014 and has held it in 45 quarters since. The position peaked at $1.09M in Q2 2015. 4,078 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Opus Capital Group held 2,030 shares of AbbVie worth $442K as of Q1 2026.
Opus Capital Group sold 629 AbbVie shares in Q1 2026, an estimated $140K.
AbbVie made up 0.05% of Opus Capital Group's portfolio in Q1 2026, its #85 holding.
Opus Capital Group first reported a position in AbbVie in Q1 2014 and has held it in 45 quarters since.
Opus Capital Group's AbbVie position peaked at $1.09M in Q2 2015.
4,078 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Opus Capital Group's 13F filing for Q1 2026, filed 30 Apr 2026.